Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy

BRAF-targeted kinase inhibitors (KIs) are used to treat malignancies including BRAF-mutant non–small cell lung cancer, colorectal cancer, anaplastic thyroid cancer, and, most prominently, melanoma. However, KI selection criteria in patients remain unclear, as are pharmacokinetic/pharmacodynamic (PK/...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Thomas S. C., Hu, Huiyu, Kronister, Stefan, Lee, Chanseo, Li, Ran, Gerosa, Luca, Stopka, Sylwia A., Burgenske, Danielle M., Khurana, Ishaan, Regan, Michael S., Vallabhaneni, Sreeram, Putta, Niharika, Scott, Ella, Matvey, Dylan, Giobbie-Hurder, Anita, Kohler, Rainer H., Sarkaria, Jann N., Parangi, Sareh, Sorger, Peter K., Agar, Nathalie Y. R., Jacene, Heather A., Sullivan, Ryan J., Buchbinder, Elizabeth, Mikula, Hannes, Weissleder, Ralph, Miller, Miles A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054019/
https://www.ncbi.nlm.nih.gov/pubmed/35486732
http://dx.doi.org/10.1126/sciadv.abl6339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054019/
https://www.ncbi.nlm.nih.gov/pubmed/35486732
http://dx.doi.org/10.1126/sciadv.abl6339

Ejemplares similares